News Releases

September 3, 2020 at 8:00 AM EDT

Summary Toggle Molecular Templates to Participate in September Virtual Investor Conferences

AUSTIN, Texas , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,
August 6, 2020 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

AUSTIN, Texas , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies
July 20, 2020 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility

AUSTIN, Texas , July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered
June 22, 2020 at 7:30 AM EDT

Summary Toggle Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time AUSTIN, Texas , June 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a
May 22, 2020 at 8:00 AM EDT

Summary Toggle Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures

AUSTIN, Texas , May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered
May 15, 2020 at 7:00 AM EDT

Summary Toggle New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II

Abstracts feature data on ETBs against clinically validated targets including PD-L1, CTLA-4, SLAMF7 and CD45 AUSTIN, Texas ,, May 15, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the
May 13, 2020 at 4:30 PM EDT

Summary Toggle Molecular Templates to Participate in Two May Virtual Investor Conferences

AUSTIN, Texas , May 13, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,
May 11, 2020 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Reports First Quarter 2020 Financial Results

AUSTIN, Texas , May 11, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies
May 7, 2020 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Announces that the 2020 Annual Meeting of Stockholders Will be Held in Virtual Format

AUSTIN, Texas , May 07, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (the “Company”) (Nasdaq: MTEM) announced today that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually due to the public health impact of the novel coronavirus outbreak (COVID-19) and to
March 12, 2020 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results

AUSTIN, Texas , March 12, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies

News Releases

News Releases

About Molecular Templates

Recent Posts

Date	Title and Summary
Toggle SummarySeptember 3, 2020	Molecular Templates to Participate in September Virtual Investor Conferences AUSTIN, Texas , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,
Toggle SummaryAugust 6, 2020	Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results AUSTIN, Texas , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies